Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

Blood (2024) 143 (23): 2363–2372.

https://doi.org/10.1182/blood.2023023502

Published: 2024

Includes: Supplemental data

Journal Articles

Clonal Dynamics of FLT3 -ITD Positive Acute Myeloid Leukemia Patients with Relapsed/Refractory Disease Following Intensive Chemotherapy +/- Midostaurin

Romane Joudinaud, Augustin Boudry, Laurène Fenwarth, Sandrine Geffroy, Mikaël Salson, Herve Dombret, Céline Berthon, Arnaud Pigneux, Delphine Lebon, Lamya Haddaoui, Raphael Itzykson, Christian Recher, Audrey Bidet, Eric Delabesse, Mathilde Hunault, Claude Preudhomme, Nicolas Duployez, Pierre-Yves Dumas

Blood (2023) 142 (Supplement 1): 976.

https://doi.org/10.1182/blood-2023-182018

Published: 2023

Journal Articles

Impact of Residence in an Agricultural Zone on AML Characteristics

Vincent Marmouset, Berengere Gruson, Veronique Harrivel, Céline Berthon, Nicolas Duployez, Claude Preudhomme, Jean Pierre Marolleau, Pierre Morel, Carine Hauspie, Stéphane Morisset, Delphine Lebon

Blood (2023) 142 (Supplement 1): 2842.

https://doi.org/10.1182/blood-2023-173171

Published: 2023

Journal Articles

Oncogenetic-Driven Targeted Therapy for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia : A French ALL-Target Observatory Report

Blood (2023) 142 (Supplement 1): 518.

https://doi.org/10.1182/blood-2023-179192

Published: 2023

Journal Articles

Mutational Profile and Dynamics of PPM1D -Mutant Clones in the Spectrum of Myeloid Disorders

Blood (2023) 142 (Supplement 1): 4064.

https://doi.org/10.1182/blood-2023-189428

Published: 2023

Journal Articles

Tetraspanin CD81 Supports Cancer Stem Cell Function and Represents a Therapeutic Vulnerability in Acute Myeloid Leukemia

Fanny Gonzales, Pauline Peyrouze, Thomas Boyer, Soizic Guihard, Francois Sevrin, Djohana Laurent, Adriana Plesa, Adeline Barthelemy, Antonino Bongiovanni, Claude Preudhomme, Nicolas Duployez, Celine Berthon, Christophe Roumier, Meyling H Cheok

Blood (2023) 142 (Supplement 1): 168.

https://doi.org/10.1182/blood-2023-186957

Published: 2023

Journal Articles

Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia

Blood (2023) 142 (Supplement 1): 1471.

https://doi.org/10.1182/blood-2023-174446

Published: 2023

Journal Articles

Standard Risk-Assessment of AML Doesn't Predict the Outcome in Older AML Patients Undergoing Non-Intensive Chemotherapy

Laura Simon, Alexis Caulier, Celine Berthon, Thomas Boyer, Véronique Harrivel, Magalie Joris, Amandine Charbonnier, Etienne Paubelle, Isabelle Leduc, Nicolas Duployez, Christophe Roumier, Claude Preudhomme, Stéphane Morisset, Jean-Pierre Marolleau, Delphine Lebon

Blood (2022) 140 (Supplement 1): 3225–3226.

https://doi.org/10.1182/blood-2022-164840

Published: 2022

Journal Articles

Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study

Blood (2022) 140 (Supplement 1): 507–509.

https://doi.org/10.1182/blood-2022-159397

Published: 2022

Journal Articles

Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study

Pilar Martínez Sánchez, Gerhard Zugmaier, Paul Gordon, Elias Jabbour, José J. Rifón Roca, Stefan Schwartz, Erika Borlenghi, Francoise Huguet, Jesús María Hernández-Rivas, Federico Lussana, Céline Berthon, Priti Kadu, Hansen Wong, Ana Markovic, Yuliya Katlinskaya, Alessandro Rambaldi

Blood (2022) 140 (Supplement 1): 6122–6124.

https://doi.org/10.1182/blood-2022-157117

Published: 2022

Journal Articles

LSC17 Score Is Complementary with Minimal Residual Disease to Stratify NPM1 -Mutated Acute Myeloid Leukemia: An ALFA Study

Blood (2022) 140 (Supplement 1): 6303–6305.

https://doi.org/10.1182/blood-2022-163348

Published: 2022

Journal Articles

Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience

Blood (2022) 140 (Supplement 1): 12335–12338.

https://doi.org/10.1182/blood-2022-163478

Published: 2022

Journal Articles

Replacing the Anthracycline By Gemtuzumab Ozogamicin in Older Patients with De Novo Standard-Risk Acute Myeloid Leukemia Treated Intensively - Results of the Randomized ALFA1401-Mylofrance 4 Study

Blood (2021) 138 (Supplement 1): 31.

https://doi.org/10.1182/blood-2021-145152

Published: 2021

Journal Articles

The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study

Blood (2021) 138 (Supplement 1): 512.

https://doi.org/10.1182/blood-2021-148843

Published: 2021

Journal Articles

Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 Trial

Blood (2021) 138 (Supplement 1): 3478.

https://doi.org/10.1182/blood-2021-150126

Published: 2021

Journal Articles

Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Blood (2021) 138 (Supplement 1): 246.

https://doi.org/10.1182/blood-2021-153286

Published: 2021

Journal Articles

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Blood (2021) 138 (7): 507–519.

https://doi.org/10.1182/blood.2021011103

Published: 2021

Includes: Supplemental data

Journal Articles

Cytokine-like protein 1–induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML

Blood (2021) 137 (24): 3390–3402.

https://doi.org/10.1182/blood.2020008729

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH -mutated AML: an ALFA study

Blood (2021) 137 (20): 2827–2837.

https://doi.org/10.1182/blood.2020010165

Published: 2021

Includes: Supplemental data

Journal Articles

Germline PAX5 mutation predisposes to familial B-cell precursor acute lymphoblastic leukemia

Blood (2021) 137 (10): 1424–1428.

https://doi.org/10.1182/blood.2020005756

Published: 2021

Includes: Supplemental data

NARROW

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

Clonal Dynamics of FLT3 -ITD Positive Acute Myeloid Leukemia Patients with Relapsed/Refractory Disease Following Intensive Chemotherapy +/- Midostaurin

Impact of Residence in an Agricultural Zone on AML Characteristics

Oncogenetic-Driven Targeted Therapy for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia : A French ALL-Target Observatory Report

Mutational Profile and Dynamics of PPM1D -Mutant Clones in the Spectrum of Myeloid Disorders

Tetraspanin CD81 Supports Cancer Stem Cell Function and Represents a Therapeutic Vulnerability in Acute Myeloid Leukemia

Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia

Standard Risk-Assessment of AML Doesn't Predict the Outcome in Older AML Patients Undergoing Non-Intensive Chemotherapy

Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study

Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study

LSC17 Score Is Complementary with Minimal Residual Disease to Stratify NPM1 -Mutated Acute Myeloid Leukemia: An ALFA Study

Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience

Replacing the Anthracycline By Gemtuzumab Ozogamicin in Older Patients with De Novo Standard-Risk Acute Myeloid Leukemia Treated Intensively - Results of the Randomized ALFA1401-Mylofrance 4 Study

The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study

Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 Trial

Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Cytokine-like protein 1–induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH -mutated AML: an ALFA study

Germline PAX5 mutation predisposes to familial B-cell precursor acute lymphoblastic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only